Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06512389
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-16
Brief Title:
Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder A Human Laboratory Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder In this double-blind within-subject placebo-controlled crossover trial participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases
Detailed Description:
Participants with alcohol use disorder will receive treatment daily 600mg cannabidiol or placebo each for 10 consecutive days with a 2-week long washout period between treatments Participants will be randomized to receive placebo or cannabidiol first in blocks of random size so that equal number of participants are allocated to each sequence Around day 8 of each treatment period participants will complete an alcohol self-administration session in the laboratory to assess the effects of treatment on alcohol consumption and alcohol-related craving
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None